Shanghai Winherb Medical Technology

Shanghai Winherb Medical Technology is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative small molecule therapeutics derived from natural products. The company focuses on high-prevalence conditions within metabolic, inflammatory, and oncological therapeutic areas. Its lead clinical program, WNC063, is a potent URAT1 inhibitor currently undergoing Phase 2 trials for the treatment of hyperuricemia and gout. Winherb leverages a proprietary drug discovery platform that combines traditional medicinal knowledge with modern high-throughput screening and lead optimization techniques. By modernizing Traditional Chinese Medicine (TCM) components into standardized pharmaceutical candidates, the company aims to provide safer and more effective treatment options for global markets.